These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18465671)

  • 21. Joint 24th Medicines for Europe and 21st International Generic and Biosimilars Association (IGBA) Annual Conference (June 13-15, 2018 - Budapest, Hungary).
    Cross G
    Drugs Today (Barc); 2018 Aug; 54(8):499-505. PubMed ID: 30209444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Let the gamification begin.
    Drell L
    Mark Health Serv; 2014; 34(1):24-7. PubMed ID: 24741765
    [No Abstract]   [Full Text] [Related]  

  • 23. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The issue of applying marketing on the pharmaceutical market in Serbia.
    Dickov V; Dickov A; Martinović-Mitrović S
    Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):275-83. PubMed ID: 21528773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
    Alván G
    Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
    [No Abstract]   [Full Text] [Related]  

  • 26. Generic medicines: solutions for a sustainable drug market?
    Dylst P; Vulto A; Godman B; Simoens S
    Appl Health Econ Health Policy; 2013 Oct; 11(5):437-43. PubMed ID: 23846572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 28. Australian drugs scheme threatens free-trade talks.
    Fickling D
    Lancet; 2004 Jan; 363(9405):299. PubMed ID: 14753208
    [No Abstract]   [Full Text] [Related]  

  • 29. Making medicines evergreen.
    Hitchings AW; Baker EH; Khong TK
    BMJ; 2012 Nov; 345():e7941. PubMed ID: 23197598
    [No Abstract]   [Full Text] [Related]  

  • 30. Analysis of French generic medicines retail market: why the use of generic medicines is limited.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):795-803. PubMed ID: 25095903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Legal aspects of on-line pharmacy: free movement of goods is not tantamount to free provision of services!
    Michel L
    Acta Chir Belg; 2004 Aug; 104(4):371-2. PubMed ID: 15469144
    [No Abstract]   [Full Text] [Related]  

  • 32. Who's really raising drug prices?
    Zagorin A
    Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
    [No Abstract]   [Full Text] [Related]  

  • 33. Legal and policy foundations for global generic competition: Promoting affordable drug pricing in developing societies.
    Zapatero Miguel P
    Glob Public Health; 2015; 10(8):901-16. PubMed ID: 25737069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The AIDS response catalysing economic and social transformation: the importance of local pharmaceutical production.
    Sidibé M
    Antivir Ther; 2014; 19 Suppl 3():3-4. PubMed ID: 25310132
    [No Abstract]   [Full Text] [Related]  

  • 35. Healing an ailing pharmaceutical system: prescription for reform for United States and Canada.
    Gaffney A; Lexchin J; ;
    BMJ; 2018 May; 361():k1039. PubMed ID: 29773533
    [No Abstract]   [Full Text] [Related]  

  • 36. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
    Sinha MS; Curfman GD; Carrier MA
    JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
    [No Abstract]   [Full Text] [Related]  

  • 39. Global generic strategy--eighth annual summit.
    Ross M
    IDrugs; 2009 May; 12(5):282-4. PubMed ID: 19431089
    [No Abstract]   [Full Text] [Related]  

  • 40. Big bad pharma: an ethical analysis of physician-directed and consumer-directed marketing tactics.
    Connors AL
    Albany Law Rev; 2009 Sep; 73(1):243-82. PubMed ID: 20235401
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.